These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
278 related articles for article (PubMed ID: 20111071)
1. Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia. Fei F; Stoddart S; Müschen M; Kim YM; Groffen J; Heisterkamp N Leukemia; 2010 Apr; 24(4):813-20. PubMed ID: 20111071 [TBL] [Abstract][Full Text] [Related]
2. Activity of the Aurora kinase inhibitor VX-680 against Bcr/Abl-positive acute lymphoblastic leukemias. Fei F; Stoddart S; Groffen J; Heisterkamp N Mol Cancer Ther; 2010 May; 9(5):1318-27. PubMed ID: 20388735 [TBL] [Abstract][Full Text] [Related]
3. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells. Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995 [TBL] [Abstract][Full Text] [Related]
4. Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells. Konig H; Copland M; Chu S; Jove R; Holyoake TL; Bhatia R Cancer Res; 2008 Dec; 68(23):9624-33. PubMed ID: 19047139 [TBL] [Abstract][Full Text] [Related]
5. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. Steinberg M Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072 [TBL] [Abstract][Full Text] [Related]
6. MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825. Nguyen TK; Rahmani M; Harada H; Dent P; Grant S Blood; 2007 May; 109(9):4006-15. PubMed ID: 17218385 [TBL] [Abstract][Full Text] [Related]
7. [Pharmacological properties and clinical efficacy of dasatinib hydrate (Sprycel), an anticancer drug for chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia]. Fujii Y; Amano M; Seriu T Nihon Yakurigaku Zasshi; 2009 Sep; 134(3):159-67. PubMed ID: 19749489 [No Abstract] [Full Text] [Related]
8. Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells. Nam S; Williams A; Vultur A; List A; Bhalla K; Smith D; Lee FY; Jove R Mol Cancer Ther; 2007 Apr; 6(4):1400-5. PubMed ID: 17431118 [TBL] [Abstract][Full Text] [Related]
9. Combined BCR-ABL inhibition with lentiviral-delivered shRNA and dasatinib augments induction of apoptosis in Philadelphia-positive cells. Myssina S; Helgason GV; Serrels A; Jørgensen HG; Bhatia R; Modi H; Baird JW; Mountford JC; Hamilton A; Schemionek M; Koschmieder S; Brunton VG; Holyoake TL Exp Hematol; 2009 Feb; 37(2):206-14. PubMed ID: 19100678 [TBL] [Abstract][Full Text] [Related]